{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:28:43Z","timestamp":1768879723632,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40744-025-00815-0","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:24:45Z","timestamp":1766496285000},"page":"231-242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Effectiveness of Baricitinib and Other b\/tsDMARDs in Patients with Rheumatoid Arthritis with Early Low Disease Activity or Remission: 2-Year Data from the RA-BE-REAL Study"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3395-4412","authenticated-orcid":false,"given":"Rieke","family":"Alten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"\u00d6st\u00f6r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Haladyj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khai Jing","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Ogwu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"3","key":"815_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/BOR.0000000000000284","volume":"28","author":"JS Smolen","year":"2016","unstructured":"Smolen JS. Treat-to-target as an approach in inflammatory arthritis. Curr Opin Rheumatol. 2016;28(3):297\u2013302.","journal-title":"Curr Opin Rheumatol"},{"key":"815_CR2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.7.882","author":"ME Peter","year":"2021","unstructured":"Peter ME, Zuckerman AD, DeClercq J, et al. Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy. J Manag Care Spec Pharm. 2021. https:\/\/doi.org\/10.18553\/jmcp.2021.27.7.882.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"815_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/acr.20021","volume":"62","author":"LH van Tuyl","year":"2010","unstructured":"van Tuyl LH, Felson DT, Wells G, et al. Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken). 2010;62(1):108\u201317.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"815_CR4","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1002\/art.22943","volume":"56","author":"D Aletaha","year":"2007","unstructured":"Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007;56(10):3226\u201335.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"815_CR5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jbspin.2019.03.008","volume":"86","author":"J Legrand","year":"2019","unstructured":"Legrand J, Kirchgesner T, Sokolova T, et al. Early clinical response and long-term radiographic progression in recent-onset rheumatoid arthritis: clinical remission within six months remains the treatment target. Jt Bone Spine. 2019;86(5):594\u20139.","journal-title":"Jt Bone Spine"},{"issue":"3","key":"815_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10067-018-4340-7","volume":"38","author":"C Yu","year":"2019","unstructured":"Yu C, Jin S, Wang Y, et al. Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. Clin Rheumatol. 2019;38(3):727\u201338.","journal-title":"Clin Rheumatol"},{"key":"815_CR7","unstructured":"Manning-Bennett A, Hopkins A, Sorich M, et al. The association of cardiovascular comorbidities with remission in rheumatoid arthritis patients undergoing treatment with baricitinib and conventional synthetic DMARDs: a post-hoc analysis [abstract]. Arthritis Rheumatol. 2022;74."},{"key":"815_CR8","unstructured":"Karpouzas G, Szekanecz Z, Baecklund E, et al. Relationship between disease activity and adverse events of interest in patients with RA on tofacitinib or TNF inhibitors: post hoc analysis of a phase 3b\/4 randomized safety study [abstract]. Arthritis Rheumatol. 2022;74."},{"key":"815_CR9","doi-asserted-by":"crossref","unstructured":"Taylor PC, Atzeni F, Balsa A, et al. The key comorbidities in patients with rheumatoid arthritis: a narrative review. J Clin Med. 2021;10(3).","DOI":"10.3390\/jcm10030509"},{"issue":"10 Suppl 1","key":"815_CR10","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.amjmed.2008.06.011","volume":"121","author":"SE Gabriel","year":"2008","unstructured":"Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121(10 Suppl 1):S9-14.","journal-title":"Am J Med"},{"issue":"10","key":"815_CR11","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1093\/rheumatology\/ket224","volume":"52","author":"VK Ranganath","year":"2013","unstructured":"Ranganath VK, Maranian P, Elashoff DA, et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology. 2013;52(10):1809\u201317.","journal-title":"Rheumatology"},{"issue":"1","key":"815_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/art.23247","volume":"59","author":"GR Burmester","year":"2008","unstructured":"Burmester GR, Ferraccioli G, Flipo R-M, et al. Clinical remission and\/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Care Res. 2008;59(1):32\u201341.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"815_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","volume":"74","author":"J Listing","year":"2015","unstructured":"Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF\u03b1 inhibitors and rituximab. Ann Rheum Dis. 2015;74(2):415\u201321.","journal-title":"Ann Rheum Dis"},{"key":"815_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002658","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Fautrel B, Piette Y, et al. Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe. RMD Open. 2022. https:\/\/doi.org\/10.1136\/rmdopen-2022-002658.","journal-title":"RMD Open"},{"issue":"2","key":"815_CR15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/bjd\/ljac059","volume":"188","author":"B King","year":"2023","unstructured":"King B, Mostaghimi A, Shimomura Y, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023;188(2):218\u201327.","journal-title":"Br J Dermatol"},{"issue":"2","key":"815_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"EC Keystone","year":"2015","unstructured":"Keystone EC. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74(2):333\u201340.","journal-title":"Ann Rheum Dis"},{"key":"815_CR17","doi-asserted-by":"crossref","unstructured":"Takagi M, Atsumi T, Matsuno H, et al. Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance. Mod Rheumatol. 2022.","DOI":"10.1093\/mr\/roac089"},{"issue":"1","key":"815_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88\u201395.","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"815_CR19","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243\u201352.","journal-title":"N Engl J Med"},{"issue":"1","key":"815_CR20","first-page":"73","volume":"10","author":"R Alten","year":"2023","unstructured":"Alten R, Burmester GR, Matucci-Cerinic M, et al. The RA-BE-REAL multinational, prospective, observational study in patients with rheumatoid arthritis receiving baricitinib, targeted synthetic, or biologic disease-modifying therapies: a 6-month interim analysis. Rheumatol Ther. 2023;10(1):73\u201393.","journal-title":"Rheumatol Ther"},{"issue":"7","key":"815_CR21","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652\u201362.","journal-title":"N Engl J Med"},{"issue":"4","key":"815_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/14397595.2017.1392057","volume":"28","author":"Y Tanaka","year":"2018","unstructured":"Tanaka Y, Atsumi T, Amano K, et al. Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: subgroup analyses of four multinational phase 3 randomized trials. Mod Rheumatol. 2018;28(4):583\u201391.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"815_CR23","doi-asserted-by":"publisher","first-page":"868","DOI":"10.55563\/clinexprheumatol\/pudtpo","volume":"39","author":"GM Guidelli","year":"2021","unstructured":"Guidelli GM, Viapiana O, Luciano N, et al. Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study. Clin Exp Rheumatol. 2021;39(4):868\u201373.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"815_CR24","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1136\/annrheumdis-2020-219699","volume":"80","author":"Y Miyazaki","year":"2021","unstructured":"Miyazaki Y, Nakano K, Nakayamada S, et al. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. Ann Rheum Dis. 2021;80(9):1130\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"815_CR25","doi-asserted-by":"publisher","first-page":"21907","DOI":"10.1038\/s41598-020-78925-8","volume":"10","author":"N Takahashi","year":"2020","unstructured":"Takahashi N, Asai S, Kobayakawa T, et al. Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry. Sci Rep. 2020;10(1):21907.","journal-title":"Sci Rep"},{"issue":"1","key":"815_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13075-024-03369-8","volume":"26","author":"S Ochi","year":"2024","unstructured":"Ochi S, Sonomoto K, Nakayamada S, Tanaka Y. Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry. Arthritis Res Ther. 2024;26(1):140.","journal-title":"Arthritis Res Ther"},{"issue":"5 Pt 2","key":"815_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.reuma.2018.10.002","volume":"16","author":"\u00c1 Acosta-M\u00e9rida","year":"2020","unstructured":"Acosta-M\u00e9rida \u00c1, Naranjo A, Rodr\u00edguez-Lozano C. Prognostic factors for sustained remission in a \u201creal life\u201d cohort of rheumatoid arthritis patients. Reumatol Clin (Engl Ed). 2020;16(5 Pt 2):405\u20139.","journal-title":"Reumatol Clin (Engl Ed)."},{"issue":"1","key":"815_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/rheumatology\/ker250","volume":"51","author":"K Jayakumar","year":"2011","unstructured":"Jayakumar K, Norton S, Dixey J, et al. Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. Rheumatology. 2011;51(1):169\u201375.","journal-title":"Rheumatology"},{"issue":"11","key":"815_CR29","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1093\/rheumatology\/key202","volume":"57","author":"N Paulshus Sundlis\u00e6ter","year":"2018","unstructured":"Paulshus Sundlis\u00e6ter N, Olsen IC, Aga A-B, et al. Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. Rheumatology. 2018;57(11):2022\u201331.","journal-title":"Rheumatology"},{"issue":"1","key":"815_CR30","doi-asserted-by":"publisher","first-page":"13908","DOI":"10.1038\/s41598-023-39711-4","volume":"13","author":"I Yoshii","year":"2023","unstructured":"Yoshii I, Chijiwa T, Sawada N. The impact of time length to Boolean remission for tight disease activity control after acquisition in rheumatoid arthritis patients. Sci Rep. 2023;13(1):13908.","journal-title":"Sci Rep"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00815-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00815-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00815-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:52:30Z","timestamp":1768834350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00815-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["815"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00815-0","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rieke Alten has received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events, and patents planned, issues, or pending from AbbVie, BMS, Celltrion, Galapagos, Janssen, Eli Lilly and Company, Novartis, Pfizer, Roche, UCB, and Viatris. Andrew \u00d6st\u00f6r has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Pfizer, Eli Lilly and Company, Novartis, and Janssen. Christopher J. Edwards received honoraria from Eli Lilly and Company, received grant payments from AbbVie, Pfizer, Roche, Biogen, and Eli Lilly and Company, received personal fees from AbbVie, Astra-Zeneca, BMS, Celltrion, Fresenius, Galapagos, Gilead, GSK, Janssen, Roche, Pfizer, and Sanofi and travel and meeting payments from Eli Lilly and Company. Josef S. Smolen received grant\/research support for his institution from: AbbVie, Astra-Zeneca, Eli Lilly and Company, Galapagos and Novartis; consultancy fees from: AbbVie, Ananda, Astro, BMS, Celltrion, Chugai, Eli Lilly and Company, Immunovant, Janssen, MSD, Novartis, Pfizer, Roche, R-Pharma, Samsung, Sanofi, and UCB. Ewa Haladyj and Khai Jing Ng are current employees and minor shareholders of Eli Lilly and Company. Yuko Kaneko received grants or speaking fees from AbbVie, Astellas, Ayumi, Bristol\u2013Myers Squibb, Chugai, Eisai, Eli Lilly and company, Jansen, Kissei, Kirin, Novartis pharma, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi, and UCB. Samuel Ogwu was an employee of Eli Lilly and Company at the time of the study and is currently affiliated with Dublin Business School, Dublin, Ireland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was conducted in accordance with Good Clinical Practice, the principles of the Declaration of Helsinki, and local laws and regulations in the five European countries. All patients provided written informed consent prior to entry to the study. Patients or the public were not involved in the design, conduct, reporting, or dissemination plans of our research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}